A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Sanofi Aventis

Protocol Number
TED10893

To Learn More Call
201-510-0910